The Orphan Drug Act was enacted 34 years ago to encourage the development of drugs for rare diseases. Drug companies were guaranteed seven years of exclusivity. Then the rush was on to run up prices.
Australia is spending more than A$500 million a year too much for pharmaceuticals because of a little known loophole that allows drug companies to overcharge the government.
The rising cost of drugs is more worrisome to most Americans than problems with Obamacare. Could proposals in California and Ohio help?
Pharmaceutical companies aim to make a profit, but it took an industry insider to blow the whistle on some exorbitant drug costs the NHS was paying.
Clinton, who named drug companies among her enemies in this week's debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
Most of us would agree that cancer drugs should be listed on the PBS, no matter how dear. But our health system can't afford all of them. How then are decisions about which drugs to subsidise made?
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
Hope, fear, and desperation, along with the unique characteristics of the cancer drug market, create a “perfect storm” that continues to drive up prices for cancer drugs.